Bacteriophage-mediated protein delivery into the central nervous system and its application in immunopharmacotherapy

Expert Opinion on Biological Therapy

Volumn 5, Issue 6, 2005, Pages 773-781

  Dickerson, Tobin J ^b   Kaufmann, Gunnar F ^b   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Cocaine abuse; Immunopharmacotherapy; Intranasal administration; Phage display

Indexed keywords

ANTIBODY; COCAINE;

ANIMAL MODEL; BACTERIOPHAGE; BEHAVIOR; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE; IMMUNOPHARMACOLOGY; NONHUMAN; PHAGE DISPLAY; RAT; REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES; CENTRAL NERVOUS SYSTEM; COCAINE; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INOVIRUS; PROTEINS; RATS;

FILAMENTOUS BACTERIOPHAGE; RODENTIA;

EID: 21044431604     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.6.773     Document Type: Review

References (62)

1. KOOB GF: Neurobiology of addiction. Toward the development of new therapies. Ann. NY Acad. Sci. (2000) 909:170-185.
2. WEISS F, KOOB GF: Drug addiction: functional neurotoxicity of the brain reward systems. Neurotoxic Res. (2001) 3:145-156.
3. MELICHAR JK, DAGLISH MR, NUTT DJ: Addiction and withdrawal-current views. Curr. Opin. Pharmacol. (2001) 1:84-90.
4. SPANAGEL R, WEISS F: The dopamine hypothesis of reward: past and current status. Trends Neurosci. (1999) 22:521-527.
5. DI CHIARA G: The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. (1995) 38:95-137.
6. JOHANSON CE, FISCHMAN MW: The pharmacology of cocaine related to its abuse. Pbarmacol. Rev. (1989) 41:3-52.
7. BLAINE JD, LING W: Psychopharmacologic treatment of cocaine dependence. Psychopharmacol. Bull. (1992) 28:11-14.
8. NO AUTHORS LISTED: Preliminary estimates from the 1992 Household Survey on Drug Abuse. Substance Abuse and Mental Health Service Administration. Office of Applied Studies. Washington, DC: US Department of Health and Human Services, Public Health Services, Advance Report No. 3, June 1993 (1993).
9. CREGLER LL, HERBERT M: Medical complications of cocaine abuse. N. Engl. J. Med. (1986) 315:1495-1500.
10. DES JARLAIS DC, FRIEDLAND SR: AIDS and IV drug use. Science (1989) 245:578-579.
11. LEE JH, BENNETT G: Substance abuse in adulthood. In: Substance Abuse: Pharmacologic, Developmental and Clinical Perspectives. Bennett G, Woolf D (Eds), Wiley, New York, USA (1991): 157-170.
12. WALSH SL: Behavioral pharmacology of cocaine. In: Handbook of Substance Abuse: Neurobehavioral Pharmacology. Tarter RE, Ammerman RT, Ott PJ (Eds), Plenum, New York, USA (1998): 187-200.
13. MENDELSON JH, MELLO NK: Management of cocaine abuse and dependence. N. Engl. J. Med. (1996) 334:965-972.
14. GORELlCK DA: Pharmacologic interventions for cocaine, crack, and other stimulant addiction. In: Principles of Addiction Medicine. Graham AW, Schultz, TK (Eds), American Society of Addiction Medicine, Chevy Chase (2003):89-111.
15. GORELICK DA, GARDNER EL, XI ZX: Agents in the development for the management of cocaine abuse. Drugs (2004) 64:1547-1573.
16. LEIDERMAN DB, SHOPTAW S, MONTGOMERY A et al.: Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction (2005) 100(Suppl. 1):1-11.
17. WINHUSEN TM, SOMOZA EC, HARRER JM et al.: A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction (2005) 100(Suppl. 1):68-77.
18. GONZALEZ G, SEVARINO K, SOFUOGLU M et al.: Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction (2003) 98:1625-1632.
19. CARROLL KM, FENTON LR, BALL SA et al.: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry (2004) 61:264-272.
20. HOUTSMULLER EJ, NOTES LD, NEWTON T et al.: Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (2004) 172:31-40.
21. SHOPTAW S, YANG X, ROTHERAM-FULLER EJ et al.: Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin. Psychiatry (2003) 64:1440-1448.
22. KAMPMAN KM, PETTINATI H, LYNCH KG et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75:233-240.
23. KAMPMAN KM, VOLPICELLI JR, MULVANEY F et al.: Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. (2001) 63:69-78.
24. rd, LUCKEY JW, FLYNN PM, HUBBARD RL: Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure. J. Addict. Dis. (1994) 13:115-128.
25. CASHMAN JR: Biocatalysts in detoxication of drugs of abuse. NIDA Research Monograph (1997) 173:225-258.
26. CARRERA MR, ASHLEY JA, PARSONS LH, WIRSCHING P, KOOB GF, JANDA KD: Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 378:727-730. This report describes the first successful use of immunopharmacotherapy for the treatment of drug addiction.
27. CARRERA MR, ASHLEY JA, ZHOU B, WIRSCHING P, KOOB GF, JANDA KD: Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA (2000) 97:6202-6206.
28. CARRERA MR, ASHLEY JA, WIRSCHING P, KOOB GF, JANDA KD: A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. USA (2001) 98:1988-1992.
29. FOX BS, KANTAK KM, EDWARDS MA et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. (1996) 2:11129-1132.
30. KANTAK KM, COLLINS SL, LIPMAN EG, BOND J, GIOVANONI K, FOX BS: Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Pychopharmacology (2000) 148:251-262.
31. LANDRY DW ZHAO K, YANG GX, GLICKMAN M, GEORGIADIS TM: Antibody-catalyzed degradation of cocaine. Science (1993) 259:1899-1901 . This report details the first example of a catalytic antibody capable of degrading cocaine.
32. CASHMAN JR, BERKMAN CE, UNDERINER GE: Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J. Pharm. Exp. Ther. (2000) 293:952-961.
33. YANG G, CHUN J, ARAKAWA-URAMOTO H et al.: Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. (1996) 118:5880-5890.
34. BAIRD TJ, DENG SX, LANDRY DW, WINGER G, WOODS JH: Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J. Pharmacol. Exp. Ther. (2000) 295:1127-1134.
35. MATSUSHITA M, HOFFMAN TZ, ASHLEY JA, ZHOU B, WIRSCHING P, JANDA KD: Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med. Chem. Lett. (2001) 11:87-90.
36. ISOMURA S, HOFFMAN TZ, WIRSCHING P, JANDA KD: Synthesis, properties, and reactivity of cocaine benzoylthioester possessing the cocaine absolute configuration. J. Am. Chem. Soc. (2002) 124:3661-3668.
37. MEIJLER MM, MATSUSHITA M, WIRSCHING P, JANDA KD: Development of immunopharmacotherapy against drugs of abuse. Curr. Drug Discov. Tech. (2004) 1:77-89.
38. GORELICK DA: Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. (1997) 48:159-165.
39. MATTES CE, BELENDIUK GW, LYNCH TJ, BRADY RO, DRETCHEN KL: Butyrylcholinesterase: an enzyme antidote for cocaine intoxication. Addiction Biology (1998) 3:171-188.
40. NACHON F, NICOLET Y, VIQUIE N, MASSON P, FONTECILLA-CAMPS JD, LOCKRIDGE O: Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. Eur. J. Biochem. (2002) 269:630-637.
41. MATTES CE, LYNCH TJ, SINGH A et al.: Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol. Appl. Pharmacol. (1997) 145:372-380.
42. SUN H, PANG YP, LOCKRIDGE O, BRIMIJOIN S: Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. (2002) 62:220-224.
43. LAROCCA D, BURG MA, JENSEN-PERGAKES K, RAVEY PE, GONZALES AM, BAIRD A: Evolving phage vectors for cell targeted gene delivery. Curr. Pharm. Biotech. (2002) 3:45-57.
44. SMITH GP: Filamentous fusion phage; novel expression vectors that display cloned antigens on the virion surface. Science (1985) 228:1315-1317.
45. CARLTON RM: Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz.) (1999) 47:267-274.
46. SMITH HW, HUGGINS RB: Successful treatment of experimental E. coli infections in mice using phage: Its general superiority over antibiotics. J. Gen. Microbiol. (1982) 128:307-318.
47. SLOPEK S, WEBER-DABROWSKA B, DABROWSKI M, KUCHAREWICZ-KRUKOWSKI A: Results in bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. (1986) 35:569-583.
48. STONE R: Stalin's forgotten cure. Science (2002) 298:728-731.
49. PASQUALINI R, RUOSLAHTI E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380:364-366. A report describing the stability of phage once injected into live animals.
50. ESSLER M, RUOSLAHTI E: Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculatures. Proc. Natl. Acad. Sci. USA (2002) 99:2252-2257.
51. DABROWSKA K, SWlTALA-JELEN K, OPOLSKI A, WEBER-DABROWSKA B, GORSKI A: Bacteriophage penetration in vertebrates. J. Appl. Microbiol. (2005) 98:7-13.
52. FRENKEL D, SOLOMON B: Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. USA (2002) 99:5675-5679. The first reported example of using phage as a vehicle for transporting displayed proteins into the CNS.
53. GAO C, MAO S, LO CH, WIRSCHING P, LERNER RA, JANDA KD: Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc. Natl. Acad. Sci. USA (1999) 96:6025-6030.
54. GAO C, MAO S, KAUFMANN G, WIRSCHING P, LERNER RA, JANDA KD: A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl. Acad. Sci. USA (2002) 99:12612-12616.
55. CARRERA MR, KAUFMANN GF, MEE JM, MEIJLER MM, KOOB GF, JANDA KD: Treating cocaine addiction with viruses. Proc. Natl. Acad. Sci. USA (2004) 101:10416-10421. A recent paper disclosing the ability of phage-displayed antibodies to enter the CNS and abrogate some of the effects of cocaine exposure.
56. BARBAS CF, BURTON DR, SCOTT JK, SILVERMAN GJ: Phage Display: A Laboratory Manual Barbas CF, Burton DR, Scott JK, Silverman GJ (Eds), Cold Spring Harbor Laboratory Press, Plainview, NY, USA (2001).
57. LYON M, ROBBINS TW: The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Current Developments In Psychopharmacology Vol. 2. Essman W, Valzelli L (Eds), Spectrum, New York, USA (1975):89-163.
58. ILLUM L, DAVIS SS: Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Delhi. Rev. (2001) 51:97-111.
59. JONES N: The nose and paranasal sinuses physiology and anatomy. Adv. Drug. Deliv. Rev. (2001) 51:5-19.
60. HANEY M, KOSTEN TR: Therapeutic vaccines for substance dependence. Expert Rev. Vaccines (2004) 3:11-18.
61. CHEN L, ZURITA AJ, ARDELT PU, GIORDANO RJ, ARAP W, PASQUALINI R: Design and validation of a bifunctional ligand display system for receptor targeting. Chem. Biol. (2004) 11:1081-1091.
62. BRESLER MM, ROSSER SJ, BASRAN A, BRUCE NC: Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl. Environ. Microbiol. (2000) 66:904-908.